Insider · CIK 0001309702
Paul J Hastings
Files at NKTX (Nkarta, Inc.), ENGN (enGene Therapeutics Inc.). First filing Jan 17, 2025, latest Jun 22, 2026.
In brief
Paul J Hastings files SEC Form 4 as CEO and director at NKTX (Nkarta, Inc.), and also at ENGN (enGene Therapeutics Inc.). Since Jan 17, 2025, Paul J Hastings has reported 0 open-market buys worth $0 and 4 open-market sells worth $100k, the latest filed on Jun 22, 2026.
A track record needs three past buys with six months of prices behind them; Paul J Hastings has 0, so none is measured yet.
The newest scored trade: sold $4,813 of NKTX on Jun 18, 2026, filed Jun 22, 2026, scored 25 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $59k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NKTX: Nkarta, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | NKTXsell Nkarta, Inc. | $4,813 1,776 shares | -0% | +72% from low-18% from high | |
| 40Moderate | Nkarta, Inc. | $54k 26,046 shares | -6% | +43% from low-25% from high | |
| 25Weak | NKTXsell Nkarta, Inc. | $3,204 1,790 shares | -1% | +33% from low-72% from high | |
| 46Moderate | Nkarta, Inc. | $38k 17,378 shares | -5% | - |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | NKTX Nkarta, Inc. | SOpen-market sale Common Stock | -1,776 | $2.71 | $4,813 | 390,247 | Jun 22, 2026 |
| Jun 16, 2026 | ENGN enGene Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +31,000 | $0.00 | $0 | 31,000 | Jun 17, 2026 |
| Jan 15, 2026 | NKTX Nkarta, Inc. | SOpen-market sale Common Stock | -26,046 | $2.07 | $54k | 390,023 | Jan 20, 2026 |
| Jan 6, 2026 | NKTX Nkarta, Inc. | AGrant or award Common Stock | +94,000 | $0.00 | $0 | 416,069 | Jan 8, 2026 |
| Jan 6, 2026 | NKTX Nkarta, Inc. | AGrant or award Stock Option (right to buy)derivative | +562,000 | $0.00 | $0 | 562,000 | Jan 8, 2026 |
| Jun 18, 2025 | NKTX Nkarta, Inc. | SOpen-market sale Common Stock | -1,790 | $1.79 | $3,204 | 320,069 | Jun 20, 2025 |
| Jun 16, 2025 | ENGN enGene Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jun 16, 2025 |
| Jun 5, 2025 | NKTX Nkarta, Inc. | AGrant or award Stock Option (right to buy)derivative | +377,000 | $0.00 | $0 | 377,000 | Jun 9, 2025 |
| Jan 15, 2025 | NKTX Nkarta, Inc. | SOpen-market sale Common Stock | -17,378 | $2.20 | $38k | 319,859 | Jan 17, 2025 |
| Jan 3, 2025 | NKTX Nkarta, Inc. | AGrant or award Common Stock | +94,500 | $0.00 | $0 | 337,237 | Jan 7, 2025 |
| Jan 3, 2025 | NKTX Nkarta, Inc. | AGrant or award Stock Option (right to buy)derivative | +565,500 | $0.00 | $0 | 565,500 | Jan 7, 2025 |
Questions about Paul J Hastings
Answered from the filings on this page, as of the latest one.
Is Paul J Hastings buying or selling?
In the last 12 months Paul J Hastings reported 0 open-market buys worth $0 and 2 open-market sells worth $59k on SEC Form 4; the latest was sold $4,813 of NKTX on Jun 18, 2026. Grants, option exercises and tax withholding are not counted.
How did Paul J Hastings's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paul J Hastings has 0.
Where does Paul J Hastings file Form 4?
Paul J Hastings has filed Form 4 at NKTX (Nkarta, Inc.) as Chief Executive Officer; ENGN (enGene Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.